Company Filing History:
Years Active: 2020
Title: Paolo B Abada: Innovator in Antibody Therapy for Hepatocellular Carcinoma
Introduction
Paolo B Abada is a notable inventor based in Indianapolis, IN (US). He has made significant contributions to the field of medical research, particularly in the development of therapies for cancer treatment. His innovative work focuses on the use of antibodies to target specific receptors involved in cancer progression.
Latest Patents
Abada holds a patent for an "Anti-VEGFR2 antibody therapy for hepatocellular carcinoma." This invention provides a human antibody that binds to the human vascular endothelial growth factor receptor 2, specifically ramucirumab. It is designed for the treatment of hepatocellular carcinoma (HCC) in patients with alpha-fetoprotein (AFP) levels of 1.5×ULN (Upper Limit of Normal) or greater. Additionally, it serves as a predictive method for treating HCC in patients with similar AFP levels. He has 1 patent to his name.
Career Highlights
Abada's career is marked by his dedication to advancing cancer therapies. His work at Imclone LLC has positioned him at the forefront of innovative cancer treatment solutions. His research has the potential to improve patient outcomes significantly.
Collaborations
Abada has collaborated with esteemed colleagues such as Shao-Chun Chang and Yanzhi Hsu. These partnerships have fostered a collaborative environment that enhances the development of effective therapies.
Conclusion
Paolo B Abada is a distinguished inventor whose work in antibody therapy is paving the way for new treatments for hepatocellular carcinoma. His contributions to medical research are invaluable and hold promise for improving cancer care.